Jan 26, 2021 / 05:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the COVID-19 neutralizing antibody program update media and investor call. (Operator Instructions) As a reminder, this conference call is being recorded. (Operator Instructions) And I will now like to turn the conference over to our host, Kevin Hern. Please go ahead, sir.
Kevin Hern - Eli Lilly and Company - VP of IR
Good afternoon. Apologies for the delay and thank you for joining us for Eli Lilly and companies SARS-coronavirus-2 neutralizing antibody program update. I'm Kevin Hern, Vice President of Investor Relations.
Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; Dr. Dan Skovronsky, Chief Scientific Officer; and Josh Smiley, Chief Financial Officer. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3. Additional information concerning factors that could cause actual results to differ
Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Transcript
Jan 26, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers